| アブストラクト | INTRODUCTION: Revumenib is a first-in-class oral inhibitor of the menin-KMT2A protein-protein interaction, approved by the United States Food and Drug Administration in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation and in October 2025 for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. The registrational program identified differentiation syndrome and (QT)-interval prolongation as adverse events of special interest. The post-marketing adverse event experience has not been systematically characterized. METHODS: A retrospective disproportionality analysis of the FDA Adverse Event Reporting System (FAERS, 14,104,743 reports) was performed, restricted to reports in which revumenib was named as a primary or secondary suspect product (n = 283). Frequentist (proportional reporting ratio with Pearson chi2; reporting odds ratio with 95% CI) and Bayesian (information component with lower 2.5% bound; empirical Bayes geometric mean [EBGM] with lower 5% bound) metrics were calculated for every adverse event reported in association with the drug. A signal required more than three reports together with concurrent fulfilment of all four disproportionality criteria. RESULTS: Twenty-eight adverse events were evaluated; nineteen met the signal definition. Differentiation syndrome produced the strongest disproportionality (EBGM 15.38, EBGM(05) 9.17). Cytopenias of every lineage, electrocardiogram QT prolonged (EBGM(05) 3.67), and lower magnitude constitutional and gastrointestinal events were also signaled. Nine events did not constitute signals, principally because of the case-count threshold. CONCLUSION: Post-marketing reporting corroborates the safety profile established in AUGMENT-101 and identifies no novel toxicity category. |